Home
NICE Guidance
Conditions and diseases
Kidney conditions
Chronic kidney disease
Chronic kidney disease
Explore
Register as a stakeholder
Show sections
Research Recommendations
Intravenous iron in children:- A prospective study of adequate duration of intravenous iron preparations in children with ana...
Trials of erythropoiesis-stimulating agents (ESAs) in children:- Trials of ESAs in children with anaemia of chronic kidney di...
Haemoglobin levels in older people:- An observational study of haemoglobin (Hb) levels and adverse outcomes in older people.
Erythropoiesis-stimulating agent (ESA) tolerance test:- A trial of an ESA tolerance test including collection of data on ESA ...
Iron levels in pre-dialysis patients:- A randomised controlled trial to assess haemoglobin (Hb) level as an outcome in pre-di...
Process of decision-making:- How should the process of decision-making about the choice of dialysis modality, including perit...
Effectiveness of modality:- What factors determine the effectiveness of any modality of dialysis, including peritoneal dialys...
Treatment sequence:- What is the most effective sequence of treatment?
Nutritional status:- Is there any significant difference in nutritional status between people on the different dialysis treat...
Evaluating effectiveness:- Which outcomes should be used in evaluating effectiveness?
Full List
Shared Learning
Embedding NICE guidance into GPSOC clinical systems
January 2017
Setting up a home dialysis programme for patients with stage 5 chronic kidney disease (CKD).
February 2012
Improving Choice for Kidney Patients and Carers - Increasing access to home dialysis
February 2011
Improving care for patients with chronic kidney disease
February 2011
Bringing the benefits of Home Haemodialysis Home
February 2011
Do not do
Supplements of vitamin C should not be prescribed as adjuvants specifically for the treatment of anaemia of chronic kidney disease (CKD).
February 2011
In people with anaemia of chronic kidney disease (CKD), androgens should not be used to treat the anaemia.
February 2011
The correction to normal levels of haemoglobin (Hb) with erythropoiesis-stimulating agents (ESAs) should not routinely be recommended in people with anaemia of chronic kidney disease (CKD).
February 2011
Supplements of folic acid should not be prescribed as adjuvants specifically for the treatment of anaemia of chronic kidney disease (CKD).
February 2011
Supplements of carnitine should not be prescribed as adjuvants specifically for the treatment of anaemia of chronic kidney disease (CKD).
February 2011
Do not diagnose CKD in people with: an eGFRcreatinine of 45 59 ml/min/1.73 m2 and an eGFRcystatinC of more than 60 ml/min/1.73 m2 and no other marker of kidney disease.
July 2014
Do not use reagent strips to identify proteinuria unless they are capable of specifically measuring albumin at low concentrations and expressing the result as an ACR.
July 2014
Do not use urine microscopy to confirm a reagent strip positive result when testing for the presence of haematuria.
July 2014
Do not use age, gender or ethnicity as risk markers to test people for CKD.
July 2014
In the absence of metabolic syndrome, diabetes or Hypertension, do not use obesity alone as a risk marker to test people for CKD.
July 2014
Full List
Guidance
Resources
Savings and productivity
Local practice